

Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

You are about to purchase a product that is not simple and may be difficult to understand

Product

Name: Aescap Genetics - Investors 10M+

ISIN code: NL0015000PR1

Name of PRIIP Manufacturer: Privium Fund Management B.V.

Contact details: www.priviumfund.com and www.aescap.com

Competent authority: Privium Fund Management B.V. is authorised and regulated by the Dutch Authority for the Financial Markets (AFM)

Date of production of this document: 12 January 2022

What is this product?



Type: The Fund is a fund for joint account (in Dutch: een fonds voor gemene rekening). It does not have a legal personality. It is formed by and comprises a contractual arrangement governed by the terms of the Prospectus between the Fund Manager, the Legal Owner and each Unit Holder.

Objectives: The Fund invests in the shares of publicly listed genetics biotech / life sciences companies. It invests in highly innovative companies that develop and market new genetics medical treatments such as gene, RNA and cell therapies. The Fund has a focused portfolio, investing in approximately 15 companies. Within this focus it will ensure that the portfolio is diversified over different diseases, development phases and geographical areas. The Fund's objective is to make an average minimum annual net return (after deduction of costs) of 20%+ over the mid-term (4-5 years).

Intended retail investor: A Well-Informed investor who either invests a minimum of EUR 10,000,000 (ten million Euro) in the Fund. The investment horizon of an investor is at least 5 years and an investor understand the risk of losing some or all of the capital invested. The minimum investment horizon is in line with the objective and investment strategy of the Fund. The investor understands the characteristics and risks associated with investing in the Fund. The Fund promotes social characteristics. In the context of the EU Sustainable Finance Disclosure Regulation (SFDR), the Fund is therefore classified as an Article 8 fund.

Maturity: The term is unlimited.

What are the risks and what could I get in return?

Risk indicator	Description of the risk-reward profile
	<div data-bbox="411 1397 1353 1473"></div> <p data-bbox="411 1480 1353 1532">←..... Lower risk Higher risk</p> <div data-bbox="411 1554 1353 1946"><p data-bbox="507 1554 1353 1583">The risk indicator assumes you keep the product for 5 years</p><p data-bbox="507 1603 1353 1655">The actual risk can vary significantly if you cash in at an early stage and you may get back less</p><p data-bbox="507 1675 1353 1753">The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.</p><p data-bbox="507 1774 1353 1852">We have classified this product as 6 out of 7, which is a high class. This rates the potential losses from future performance at a high level, and poor market conditions could impact the capacity of the Aescap Genetics to pay you.</p><p data-bbox="507 1872 1353 1928">This product does not include any protection from future market performance so you could lose some or all of your investment.</p></div>

If (we) (are) not able to pay you what is owed, you could lose your entire investment.				
Performance scenarios	Investment EUR 10,000			
	Scenarios	1 year	3 years	5 years (recommended holding period)
Stress scenario	What you might get back after costs	EUR 4,871	EUR 4,064	EUR 2,990
	Average return each year	-51.3%	-25.9%	-21.5%
Unfavourable scenario	What you might get back after costs	EUR 8,378	EUR 8,441	EUR 9,080
	Average return each year	-16.2%	-5.5%	-1.9%
Moderate scenario	What you might get back after costs	EUR 11,121	EUR 13,286	EUR 17,190
	Average return each year	11.2%	11.4%	11.4%
Favourable scenario	What you might get back after costs	EUR 14,890	EUR 22,842	EUR 32,823
	Average return each year	48.9%	31.7%	26.8%

This table shows the money you could get back over the next five years, under different scenarios, assuming you invest EUR 10,000.

The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products.

The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and are not an exact indicator. What you get will vary depending on how the market performs and how long you keep the investment.

The stress scenario shows what you might get back in extreme market circumstances, and it does not take into account the situation where we are not able to pay you.

The figure shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What happens if Privium Fund Management B.V. is unable to pay out?

The product's assets are held separately from Privium Fund Management B.V. A pay-out of the product's assets is thus not affected by the financial position or potential default of Privium Fund Management B.V.

The Legal Owner holds the legal ownership of the Fund Assets as required by law.

What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs. The amounts shown here are the cumulative costs of the product itself, for three different holding periods. They include potential early exit penalties. The figures assume you invest EUR 10,000. The figures are estimates and may change in the future.

Costs over time	The person selling you, or advising you, about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.
	Investment EUR 10,000

Scenarios	If you cash in after 1 year	If you cash in after 3 years	If you cash in after 5 years (recommended holding period)
Total costs	Euro 162.-	Euro 486.-	Euro 810.-
Impact on return (RIY) per year	1.62%	1.62%	1.62%

Composition of costs	The table below shows:			
	<ul style="list-style-type: none"> The impact each year of the different types of costs on the investment returns you might get at the end of the recommended holding period; and The meaning of the different cost categories 			
	This table shows the impact on return per year			
	One-off costs	Entry costs	0.05% (for the benefit of the fund)	The impact of the costs you pay when entering your investment.
		Exit costs	0.05% (for the benefit of the fund)	The impact of the costs of exiting your investment when it matures.
	On-going costs	Portfolio transaction costs	0.03%	The impact of the costs of us buying and selling underlying investments for the product.
		Other ongoing costs	1.62%	The impact of the costs that we take each year for managing your investments.
Incidental costs	Performance fees	18%	The impact of the performance fee. We take these from your Net New Appreciation, if any, achieved by the Fund during the performance period, subject to a high water mark limitation.	
	Carried interests	N/A	The impact of carried interests.	

How long should I hold it and can I take money out early?

Recommended holding period: 5 years

Units may only be redeemed on Redemption Dates with due notice. No partial redemptions will be permitted if, immediately thereafter, the value of a redeeming Unit Holder's holding would be less than the minimum holding permitted, unless approved by the Fund Manager in its sole and absolute discretion. Shares may not be redeemed when the calculation of the NAV is suspended.

Investing in biotech companies involves a high degree of risk and prices of the securities of such companies, especially of companies with a small market cap, may be volatile. Furthermore, there is concentration risk because of the genetics biotech focus and a relatively concentrated portfolio. Therefore, a longer term holding period is recommended.

How can I complain?

Should you have a complaint, you can contact Privium Fund Management B.V. by email, telephone or post.

Email: complaints@priviumfund.com

Telephone: +31 20 46 26 644

Post: Gustav Mahlerplein 3, 26th floor, Financial Offices, 1082 MS Amsterdam

Other relevant information

We are required to provide you with further documentation, such as the product's latest prospectus and annual reports. These documents and other product information are available online at www.priviumfund.com and www.aescap.com